to Assess the Safety of Ga68-Dolacga Injection in Healthy Volunteers

Safety Issues Clinical Trial

Official title:

An Open-label Phase I Clinical Trial to Assess the Safety of Ga68-Dolacga Injection in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03908957
• Other study ID #: PTK16081821
• Status: Completed
• Phase: Phase 1
• Start date: February 12, 2019
• Est. completion date: August 9, 2019

Study information

• Verified date: February 2020
• Source: Institute of Nuclear Energy Research, Taiwan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1 study to evaluate the safety of Ga68-Dolacga Injection in healthy volunteers and to assess the normal reference range and inter-individual variability of the Ga68-Dolacga Injection in estimating liver reserve in healthy volunteers.

Description:

Ga-68 is a positron-emitting radionuclide with short half-life of 68 minutes. Dolacga is a non-radiolabeled formulated drug product and will be reconstituted to become the finished radiopharmaceutical product Ga68-Dolacga Injection, a PET tracer specifically targeting to surface receptors of hepatocytes. The study aims to evaluate the safety of Ga68-Dolacga Injection in healthy volunteers and to assess the normal reference range and inter-individual variability of the Ga68-Dolacga Injection in estimating liver reserve in healthy volunteers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: August 9, 2019
• Est. primary completion date: August 9, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent must be obtained before any assessment is performed.

2. Male or female subjects aged 20 or above, inclusive, at date of consent.

3. Body mass index (BMI) between 18.5 and 23.0, inclusive, (BMI will be calculated as weight in kilogram [kg]/height in meters2 [m2])

4. Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal ligation) or post-menopausal for at least 1 year or, if they are of child-bearing potential, must commit to use a barrier contraception method for the duration of the study.

5. Male subjects and their partners of childbearing potential must commit to the use of two methods of contraception, one of which is a barrier method for male subjects for the study duration.

6. Male subjects must not donate sperm for the study duration.

7. Willing and able to cooperate with study procedures

8. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, and ECG

9. Laboratory values within reference range, unless values are deemed by the Principal Investigator as "Not Clinically Significant"

10. Negative result for hepatitis B and C antigen test

Exclusion Criteria:

1. Known or suspected allergy, hypersensitivity, or intolerance to any ingredients of study product as stated in this protocol

2. Implantation of metal devices including cardiac pacemaker, intravascular metal devices

3. Current or prior history of major psychiatric disorders, epilepsy and major depression

4. History of positive test for human immunodeficiency virus (HIV)

5. History of chronic alcohol or drug abuse within the last 6 months

6. Pregnant women, lactating or breast-feeding women

7. Clinically significant abnormal laboratory values and/or clinically significant or unstable medical illness

8. General PET exclusion criteria

9. Prior participation in nuclear medicine treatments or computer tomography examinations in the last year

10. Subject has received an investigational drug or device within 30 days of screening.

11. Subjects having high risks for the study according to the PI discretion

12. Subjects who can't be followed up for any reason

Related Conditions & MeSH terms

• Safety Issues

Intervention

Drug:
• Ga68-Dolacga Injection
Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei City

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Nuclear Energy Research, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects reporting clinically significant changes in serum biochemical tests		from pre-dose to 14±2 days post dose
Primary	Number of subjects reporting clinically significant changes in hematological tests		from pre-dose to 14±2 days post dose
Primary	Number of subjects reporting clinically significant changes in urinalysis		from pre-dose to 14±2 days post dose
Primary	Number of subjects with clinically significant changes in systolic blood pressure and diastolic blood pressure		from pre-dose to 14±2 days post dose
Primary	Number of subjects with body temperature abnormalities		from pre-dose to 14±2 days post dose
Primary	Abnormalities of physical examination in visit 2 (post-treatment) compared with visit 1	Including the examination of general appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities, vascular and neurological	visit 2 (Day 1)
Primary	Number of subjects with clinically significant changes in Heart Rate		from pre-dose to 14±2 days post dose
Primary	Number of subjects with clinically significant changes in electrocardiogram(ECG)	The ECG parameters include: PR interval (milliseconds), QTc interval (milliseconds), QRS duration (milliseconds)	from pre-dose to 14±2 days post dose
Primary	Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)	All laboratory abnormalities which are compared with screening values and out of the reference range will be considered as AE and will be assessed its relationship to the study drug. Any ECG changes including ECG waveform will be assessed as AE(s) and will be followed to assess whether they resolved and when they resolved.	14 days
Secondary	Establishment of the normal reference range of the percent of injection dose (%ID) in healthy liver	The normal reference range will be measured by the mean +/- standard deviation of the liver %ID of all of the phase 1 volunteers.	up to 60 minutes after administration of Ga68-Dolacga Injection